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Abstract
AIM: Microsatellites are the repeated DNA sequences
scattered widely within the genomes and closely linked
with many important genes. This study was designed to
characterize the changes of microsatellite DNA loss of
heterozygosity (LOH) in esophageal carcinogenesis.
METHODS: Allelic deletions in 32 cases of matched
precancerous, cancerous and normal tissues were examined
by syringe microdissection under an anatomic microscope
and microsatellite polymorphism analysis using 15
polymorphic markers on chromosomes 3p, 5q, 6p, 9p, 13q,
17p, 17q and 18q.
RESULTS: Microsatellite DNA LOH was observed in
precancerous and cancerous tissues, except D9S1752.
The rate of LOH increased remarkably with the lesions
progressed from basal cell hyperplasia (BCH) to squamous
cell carcinoma (SCC) (P<0.05). Three markers, D9S171,
D13S260 and TP53, showed the highest incidence of LOH
(>60%). LOH loci were different in precancerous and
cancerous tissues. LOH in D3S1234 and TP53 was the
common event in different lesions from the same patients.
CONCLUSION: Microsatellite DNA LOH occurs in early
stage of human esophageal carcinogenesis, even in BCH.
With the lesion progressed, gene instability increases, the
accumulation of this change may be one of the important
mechanisms driving precancerous lesions to cancer.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Esophageal carcinoma (EC) is one of the six most common
malignant diseases in the world with a remarkable geographical
distribution. The prognosis of EC is very poor, its 5-year
survival rate is only about 10% for the patients at late or
advanced stage. Linzhou city (formerly Linxian) and nearby
counties in Henan Province, China, have been well recognized
as the high incidence area in the world. In the past years,
scientists from China and other countries have made much
research work in this area and found that esophageal
carcinogenesis was a multistep progressive process characterized
by multiple genetic changes (accumulation and overlap). The
early characteristic of the subjects predisposed to EC is the
abnormal proliferation of  epithelial cells, morphologically
manifested as basal cell hyperplasia (BCH), dysplasia (DYS)
and carcinoma in situ (CIS), which could be considered as
precancerous lesions of EC. The precancerous lesions are
instable, i.e., they can develop to cancer, or stay for a couple
of  years without any changes, or even return to normal.
What is the most important factor to decide the precancerous
lesions to develop in different directions, especially in those
with a similar morphology? What is the key point to induce
mild precancerous lesions to develop cancer? Our assumption
is that there exist different molecular changes in precancerous
lesions with a similar morphology. To characterize the
molecular changes in carcinogenesis of EC, the mechanism
of EC could be elucidated and the biomarkers for early
diagnosis and mass survey of  high-risk populations could
be established[1].
Microsatellites are the repeated DNA sequences scattered
widely within the genomes and closely linked with many
important genes[2]. In recent years many researches have
indicated that the alteration of microsatellite DNA is one
of  the important markers, which could induce normal cells
to undergo immortal and neoplastic transformations. It was
reported that an extensive loss of microsatellite DNA was
discovered in many tumors such as colon cancer. Some
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microsatellite loci often exist in the hot spots of LOH at a
high frequency in some specific malignancies. Tumor
suppressor genes, which are associated with the development
and progression of tumors, may harbor in the vicinity of these
hot spots.
To characterize the changes of  microsatellite DNA in
esophageal carcinogenesis, loss of heterozygosity (LOH) in
specific loci was analyzed in 32 surgically resected EC
specimens using microsatellite polymorphic markers. Allelic
deletions were examined using 15 polymorphic markers on
chromosomes 3p, 5q, 6p, 9p, 13q, 17p, 17q and 18q.
MATERIALS AND METHODS
Precancerous and cancerous tissues
Thirty-two surgically resected squamous cell carcinoma
(SCC) specimens were collected from Linxian Country, a
high-incidence area of EC in Henan Province, China. Of
the EC patients, 18 were males and 14 were females with
an average age of 59 years (range 44-73 years). All the
SCC patients were not treated by either chemotherapy or
radiotherapy before operation. Surgically resected specimens
were divided into two parts: One was fixed with 85% ethanol
and paraffin embedded for histopathological diagnosis, and
the other was stored in liquid nitrogen and then transferred
in a -80 ℃ freezer for further use. Ten of  thirty-two cases
were taken from cancer and adjacent tissues. Various tissues
from cancer and adjacent parts were frozen and cut into
5-m thick sections and 30-60 slides were used for DNA
extraction and LOH analysis. Five slides were stained with
hematoxylin-eosin (HE) for histopathological diagnosis.
According to cell morphologic changes, the esophageal epithelia
were divided into BCH, DYS, CIS and SCC[3].
Syringe microdissection under anatomic microscope and DNA
extraction
According to the distribution of cells in HE-stained sections,
we dropped glycerol in matched spots, separated precancerous,
cancerous and normal cells by a 5-mL syringe under an anatomy
microscope, put them into 180 L lysis buffer, added 20 L
proteinase K (50 g/L), and kept overnight at 56 ℃. By
this method, 90% purified cells could be collected[4]. DNA
was extracted according to the protocols of  the QIAGEN
DNA Mini Kit.
LOH analysis
According to the results based on our previous work in
esophageal carcinogenesis at high-incidence area for EC in
Henan Province, China[5], we chose 15 microsatellite DNA
loci for LOH analysis using a circulating p53-Rb system.
These loci represented D3S966 (RASSF1A), D3S1234 and
D3S1300 (FHIT), D5S82 (DP1), D5S346 (APC), D6S497
(HLA, Waf1), D9S1752 (INK4a), D9S171 (INK4b), D13S260
(BRCA2), D13S321 and D13S233 (Rb1), TP53 and D17S786
(p53), D17S855 (BRCA1) and D18S858 (DCC).
Microsatellite polymorphism analysis
Each locus was amplified from 40 to 50 ng of template
DNA by PCR using paired primers, of which the forward
primer was 5’ end-labeled with [-32P] ATP. Eight percent
of nondenaturing polyacrylamide gel electrophoresis was
performed at 1 650 V for 2-3 h. After electrophoresis, the
gel was transferred to a 3 MM chromatography paper and
dried in a vacuum gel dryer at 80 ℃ for 1 h. The dried gel
was placed into an X-ray film cassette with an intensifying
screen and exposed to a Kodak film at -70 ℃ or at room
temperature for 2-48 h.
Result determination
Three individuals examined the relative intensities of
polymorphic alleles in different lesions. LOH status was
established if the intensity of one allele in the tumor was
significantly reduced as compared with its corresponding
allele in constitutive DNA. When the decision was not
unanimous, the density of  alleles was determined by quantitative
densitometry. Reduction of 30% intensity of one allele in
tumor DNA compared to its matching allele in the constitutive
DNA was chosen as the criteria for LOH status. Individual
results were classified into three categories: LOH (loss of
one allele), heterozygosity retained (no allelic loss), and
uninformative (homozygous alleles)[6].
Statistical analysis
The data were analyzed by SPSS10.0 statistical software.
LOH frequency was performed by 2 test. P<0.05 was
considered statistically significant.
RESULTS
Relationship between LOH frequency and lesions (Figures 1
and 2, Table 1)
Microsatellite DNA LOH was observed in precancerous
and cancerous tissues, except D9S1752. The rate of LOH
increased remarkably with the lesion developed from BCH
to SCC (P<0.05). At least on LOH locus was 41% (7/17)
in BCH, 82% (14/17) in DYS, 100% (17/17) in CIS and
97% (31/32) in SCC. Three samples from SCC and one
sample from CIS were found to have deletions in 18 loci.
Distribution of microsatellite DNA LOH in different lesions
(Figure 3)
LOH loci were different in precancerous and cancerous
tissues. In BCH, DYS and SCC, the highest LOH loci
were TP53 (20%), D13S260 (33.3%) and TP53 (68.2%)
respectively. In CIS, the highest LOH markers had three
loci, D13S260, D9S171 and D3S966 (50%). Three markers,
D9S171, D13S260 and TP53, showed the highest incidence
of LOH (>60%). LOH in D3S1234 and TP53 was the
common event in different lesions of the same patients.
DISCUSSION
Inactivation of tumor suppressor genes appears to be one
of the genetic mechanisms involved in the development of
esophageal cancer. This process includes mutation of one
allele, followed by a deletion of the remaining one (LOH)
or homozygous deletion of both alleles. Allelic deletions
detected as LOH have been proved useful for mapping
regions of DNA that contain tumor suppressor genes[7].
LOH at specific chromosomal regions strongly suggested
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the existence of tumor suppressor genes at the relevant
segments[8]. We performed deletion mapping analyses in 32
cases of  matched precancerous, cancerous and normal
tissues using 15 microsatellite markers on chromosomes
3p, 5q, 6p, 9p, 13q, 17p, 17q and 18q and found that
microsatellite DNA LOH occurred in early precancerous
stage and in BCH. With the development of the disease,
the rate of LOH increased, indicating that the genetic
changes occurred in the early stage of EC. With the lesion
progressed, gene instability increased, the accumulation of
this change may be one of the important mechanisms
transforming precancerous lesions to cancer. LOH loci were
different even at the same stages (such as DYS), indicating
that there existed different molecular changes in precancerous
lesions with a similar morphology. These changes might be
the key factors to decide precancerous lesions developing
in different directions, especially in those with a similar
morphology. Esophageal carcinogenesis is a multistep
progressive process characterized by multiple genetic changes
(accumulation and overlap). The changes of  p15INK4b, BRAC2
and p53 genes are common molecular events in esophageal
carcinogenesis. LOH in D3S1234 and TP53 is the common
event in different lesions of patients, indicating that the
alternations of fragile histidine triad (FHIT) and p53 might
be the key points to induce mild precancerous lesions to
cancer. RASSF1A - one of the candidate TSGs - might be
Figure 1  Allelic deletion patterns in TP53 microsatellite loci. Arrows indicate LOH in different lesions. B: basal cell hyperplasia (BCH),
D: dysplasia (DYS), C: carcinoma in situ (CIS), S: squamous cell carcinoma(SCC), N: normal tissue, A: LOH in BCH; B: LOH in DYS; C: LOH in CIS;
D: LOH in SCC.
Figure 2  Allelic deletion patterns of various microsatellite markers in ESCC. Paired tumor DNA (T) and non-neoplastic DNA (N) were
examined for each case. Arrows indicate LOH in tumor samples. A: D3S966 LOH; B: D6S497 LOH; C: D9S1752 LOH; D: D13S233 LOH; E: TP53
LOH; F: D18S858 LOH.
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involved in the esophageal carcinogenesis in Henan Province,
China.
The p15INK4b gene is an inhibitor of cyclin-dependent
kinase 4, which has been identified in 95% genome sequence
homogeneity with p16INK4a. They encode two important
cyclin-dependent kinase inhibitors, which could negatively
regulate G1-S transition of the proliferating cells by contributing
to the maintenance of pRb in an active state[9]. Xing et al[10],
reported that both p15INK4b and p16INK4a genes were frequently
inactivated in EC, but the inactivation of p15INK4b and p16INK4a
involved different mechanisms, with p16INK4a predominantly
affected by aberrant methylation and p15INK4b by deletion.
We analyzed the allelic loss of  p15INK4b and p16INK4a using
D9S1752 and D9S171 microsatellite markers, and found
that the LOH frequency of p15INK4b was much higher than
that of p16INK4a in precancerous and cancerous lesions. Our
results support the speculation of  Xing et al[10], and suggest
that the deletion of p15INK4b gene might be involved in the
multistage development of EC at the high-incidence area
in Henan Province, China. LOH of p16INK4a might not be
an important event in the esophageal carcinogenesis in the
area.
BRCA1 and BRCA2 are tumor suppressor genes in
familial breast-ovarian carcinoma syndrome and are located
in different chromosomes. The BRCA2 gene is located on
chromosome 13q12[11]. Extensive genetic and biochemical
characterization has shown that BRCA2 is involved in the
maintenance of  chromosomal stability. It could serve as a
critical mediator of DNA repair through direct interactions
with Rad51 and might play an important role in recombination-
mediated double-strand DNA break repair[12]. Harada et al[13],
performed a fine deletion mapping on 13q by analyzing
60 EC patients with 18 polymorphic markers and found
the frequent loss at D13S260 (43.7%). Up to now, to our
knowledge, there are no other reports on the changes of
BRCA2 in precancerous tissues. In our experiment, BRCA2
gene alternations were detected as 0% in BCH, 33% in
DYS, 50% in CIS, and 61.5% in SCC, indicating that the
deletion of BRCA2 might be involved in the development
of EC and is one of the common molecular events in the
esophageal carcinogenesis.
The p53 tumor suppressor gene is located on chromosome
Table 1  Comparison between frequency of microsatellite LOH in different lesions of esophagus
            LOH frequency n (%)
MSM    P
     BCH      DYS CIS          SCC
D3S1234 1/14 (7.1) 3/12 (25) 5/15 (33.30)   9/23 (39.1) 0.042
D3S1300 0/11 (0) 2/10 (20) 4/10 (40) 10/26 (38.5) 0.024
D3S966 0/13 (0) 3/13 (23.1) 8/16 (50) 11/20 (55.0) 0.001
D5S82 0/12 (0) 2/12 (16.7) 6/15 (40)   8/20 (40.0) 0.010
D5S346 2/12 (16.7) 3/12 (25) 4/10 (40) 14/25 (56.0) 0.011
D6S497 0/10 (0) 0/13 (0) 0/12 (0)   9/26 (34.6) 0.001
D9S1752 1/15 (6.7) 2/12 (16.7) 3/15 (20)   5/25 (20.0) 0.315
D9S171 0/13 (0) 5/16 (31.3) 7/14 (50) 14/23 (60.8) 0.000
D13S233 0/11 (0) 3/13 (23.1) 6/16 (37.5) 10/21 (47.6) 0.006
D13S321 0/14 (0) 3/12 (25) 6/14 (42.9) 11/25 (44.0) 0.006
D13S260 0/16 (0) 4/12 (33.3) 7/14 (50) 16/26 (61.5) 0.000
D17S855 2/13 (15.4) 4/14 (28.6) 6/15 (40) 14/26 (53.8) 0.014
TP53 3/15 (20) 4/13 (30.8) 7/16 (43.8) 15/22 (68.2) 0.002
D17S786 0/14 (0) 3/12 (25) 6/15 (40) 12/22 (54.5) 0.001
D18S858 0/13 (0) 3/16 (18.8) 4/12 (33.3) 10/18 (55.6) 0.000
MSM: microsatellite marker; LOH: loss of heterozygosity; BCH: basal cell hyperplasia DYS: dysplasia; CIS: carcinoma in situ; SCC: squamous cell carcinoma -: not done.
Figure 3  Distributions of microsatellite DNA-LOH in different precancerous lesions of esophagus FAL: fractional allelic loss for each tumor
○ retention of heterozygosity ■ loss of heterozygosity Ø uninformative, X not done.
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17p13.1 and encodes a 53 ku nuclear phosphoprotein that
binds to DNA and blocks the progression of the cell cycle
in response to DNA damage and mediates apoptosis[14].
Allelic loss of p53 gene on chromosome 17p13.1 has been
demonstrated to be one “hit” of inactivation of p53 gene.
It was reported that the frequencies of LOH ranged from
65% to 83.8%, and often co-existed with mutations (“two
hits”) in EC[15]. In our experiments, the deletion of p53
occurred in the early stage of BCH (20%), indicating that
the alternations of p53 might be the key points to induce
mild precancerous lesions to cancer.
Frequent allele loss has been observed on chromosome
3p in EC and its premalignant lesions, indicating that inactivation
of putative tumor suppressor genes on 3p may be involved
in early stages of esophageal carcinogenesis. It has been
reported that FHIT gene is a novel tumor suppressor gene
located on chromosome 3p14.2[16]. Highly frequent abnormal
transcripts of FHIT gene have been found in a variety of
human cancers, including cancers of the digestive tract,
lung, breast, and head and neck[17,18]. Point mutations of  the
FHIT gene were also seen in gastric and breast carcinomas,
but very rarely. A review of the literature showed that
different results were obtained by different researches[19-21].
Zou et al[19], reported that the deletions of FHIT were
involved in 11 of 50 (22%) EC samples. On the other hand,
Mori et al[22], observed that the LOH frequency of  the FHIT
gene was 76%. In our experiment, loss of FHIT was
detectable in 7% BCH, 20% DYS, 33% CIS and 39% SCC.
Although the LOH frequency of FHIT gene was low in
our results, the change occurred in each stage of esophageal
carcinogenesis. Exposure to different environmental carcinogens
might be one of the reasons why there existed differences
in different areas.
RASSF1A is a novel tumor suppressor gene that was isolated
recently from the lung tumor suppressor locus 3p21.3[23].
The presence of a Ras associated domain in RASSF1A
suggested that this protein might function as an effector of
Ras signaling in normal cells. Its protein structure also
suggested that RASSF1A might participate in the DNA
damage response or in DNA damage-induced regulation
of other cell signaling events[24]. Chan et al[25], demonstrated
the methylation status of RASSF1A and the frequency of
LOH in 3p21.3 region in bladder cancer and found that the
frequency of LOH and methylation of RASSF1A were
57.9% and 47.5% respectively, showing that RASSF1A
might be inactivated in accordance with the two-hit
inactivation model, involving deletion of one allele and
hypermethylation of  the other[26]. Up to now, much research
work has been done in promoter hypermethylation of
RASSF1A. In the present study, we observed that the LOH
frequency of  D3S966 was 23.1% in DYS, 50% in CIS and
55% in SCC, indicating that RASSF1A might be involved
in the esophageal carcinogenesis at the high-incidence area
in Henan Province, China. To our knowledge, this report is
the first to identify allelic loss of RASSF1A during esophageal
carcinogenesis in Henan Province, China.
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